Log in to your Inderes Free account to see all free content on this page.
Genmab
1,591
DKK
-0.09 %
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-0.09%
+6.6%
+2.71%
-0.5%
-9.34%
-26.51%
-32.93%
+9.27%
+4,565.69%
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
105.3B DKK
Turnover
140.07M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.2.
2025
Annual report '24
12.3.
2025
General meeting '25
8.5.
2025
Interim report Q1'25
ShowingAll content types
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio